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There are questions about the risk-benefit balance of longer-term antipsychotic medication 
treatment following first episode psychosis, especially in relation to relapse because of 
dopamine supersensitivity following treatment cessation.  
Aim 
To determine whether hospitalization rates in first episode psychosis patients are associated 
with length of initial oral antipsychotic medication exposure. 
Methods 
We examined psychiatric hospitalization rates in patients experiencing first episode of 
psychosis from the total population of Sweden between 1 January 2007 and 31 December 
2016 (N=7043). We categorized patients by the length of first antipsychotic treatment (<6m, 
6m to <1yr, 1yr to <2yrs, 2yrs to <5yrs and 5yrs). 
Results 
Compared to those treated for <6 months, individuals receiving oral antipsychotic 
medications for 5 years had less than half the cumulative incidence of hospitalization at all 
times between 1 and 4 years after treatment cessation.  
Conclusion 
We found no evidence that hospitalization rates increased with increasing baseline 
antipsychotic exposure. 





Guidelines recommend continuing antipsychotic treatment following first episode of 
psychosis (FEP) for 1-2 years (Correll et al., 2018). In recent years, questions have been 
raised about the necessity of longer-term treatment in this population (Leucht, 2018). It has 
been argued that prolonged antipsychotic treatment may increase rebound psychosis and 
relapse risk, potentially via dopamine supersensitivity (Murray et al., 2016). We are aware of 
only one population-based study which supports this hypothesis (Tiihonen et al., 2018) and 
there is limited, discrepant evidence from studies in animals and humans (Goff et al., 2017). 
We aimed to determine hospitalization rates in individuals with FEP following different 




For this study we used Swedish linked National Patients registers, which have complete 
population coverage from 1973 and 2006 for inpatient and outpatient services respectively, 
and the Prescribed Drug register, which is complete from 1 July 2005 onwards. We limited 
our definition of FEP to individuals receiving a diagnoses of schizophrenia (ICD-9: 295A-E, 
G, W, X; ICD-10: F20) and non-affective psychoses (ICD-9: 297, 298B-E, W, X; ICD-10: 
F21-24, F28-F29) in the National Patient Register after 1 January 2007. As we wanted to 
study an incident FEP cohort we only included individuals aged 16-35 and excluded 
individuals who received a diagnosis of schizophrenia, non-affective psychosis or bipolar 
disorder, or were treated with antipsychotic medication, before 1 January 2007. We 
categorized first oral antipsychotic medication exposure as: <6m, 6m to <1yr, 1yr to <2yrs, 
2yrs to <5yrs and 5yrs. We used prescription dates and a three-month repeat prescription 
window to define periods of continuous prescribing in patients with 2 prescriptions. 
Individuals were followed up from the date they stopped taking antipsychotic medication to 
the earliest of: psychiatric hospitalization, restarting antipsychotic medication, death, 
migration out of Sweden, or 31 December 2016.  We performed Fine-Gray competing risks 
regression (Fine and Gray, 1999; Austin and Fine, 2017) with psychiatric hospitalization as 
the outcome and restarting antipsychotic medication or death as competing events. This 
produces a subdistribution hazard ratio, which is the difference in rate between exposure 
groups in patients who are event free or have experienced a competing event (reintroduction 
of antipsychotic medication, or death), and estimates the cumulative incidence function for 
hospitalization. 
 
We adjusted for age, sex, calendar year, diagnosis (schizophrenia vs. non-affective 
psychosis), percentage of days spent as inpatient during first antipsychotic exposure (as a 
proxy for severity), history of substance misuse diagnosis, and antipsychotic type at baseline 
(using the seven antipsychotic medication neuroscience based nomenclature groupings 
Zohar et al., 2015). Ethical approval for the study was obtained via the Regional Ethical 
Review Board in Stockholm. 
 
Results 
Psychiatric hospitalization occurred in 1,323 of the 7,043 patients during follow-up (Figure 1, 
Table 1). There was an inverse relationship between duration of the patient’s first oral 
antipsychotic exposure and cumulative incidence of hospitalization (Figure 2). Individuals 
exposed to antipsychotic medication for 5 years had an adjusted subdistribution hazard 




Duration of baseline antipsychotic treatment was inversely associated with rate of 
hospitalization after stopping treatment in FEP. Compared to those treated for <6 months, 
individuals receiving antipsychotic medications for 5 years had less than half the 
cumulative incidence of hospitalization at all times between 1 and 4 years after treatment 
cessation. In all groups, hospitalization rate was most rapid in the first 6 months after 
treatment cessation.  
 
Our results run contrary to the findings of Tiihonen and colleagues (2018), the only previous 
study of this type in a population cohort of which we are aware. Tiihonen et al., (2018) found 
lowest hospitalization rates in patient’s never stopping antipsychotics, then those stopping 
immediately, with increasing rates over increasing duration of treatment before cessation. An 
analytical difference is that they used a Cox proportional hazards model, whereas we 
considered the competing risk of restarting antipsychotic medication, which substantially 
modifies the chance of hospitalization (Fine and Gray, 1999). However, if we treat our data 
in the same way (censoring at the point of restarting antipsychotic medication), we find no 
association between baseline antipsychotic exposure length and hospitalization, so this does 
not explain the discrepancy. Our cohort contained no one permanently exposed to 
antipsychotics and no one stopping immediately; such individuals may be atypical FEP 
cases. Our competing risks approach gives a more accurate estimate of cumulative 
incidence of hospitalization.  
 
Despite multivariable adjustment, our results remain vulnerable to unmeasured confounding, 
especially relating to confounding by indication, and time-modified confounding. Our 
approach may misclassify antipsychotic exposure periods, and we cannot guarantee that 
repeat collection of prescriptions means adherence to medication, but this would bias our 
results toward the null.  
 
Our study does not support the hypothesis that longer antipsychotic medication exposure 
increases the rate of relapse after stopping treatment. Although this hypothesis has been 
widely discussed in recent years (Leucht, 2018; Murray et al., 2016; Tiihonen et al., 2018), 
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 Figure 1. Flow diagram of potentially included patients 
 
Figure 2. Hospitalization incidence in the first 4 years following antipsychotic 







Table 1. Patient characteristics by duration of antipsychotic treatment  
 Duration of antipsychotic treatment in first episode psychosis 
Baseline 
characteristics  
<6m 6m to  
<1yr 




N 3,045 1,838 1,196 821 143 





































Percentage of days 
spent as inpatient 
during first treatment, 
range 
0-86% 0-82% 0-40% 0-48% 0-46% 
























* Mean 6.34, standard deviation 1.04 years 
 
Table 2. Psychiatric hospitalization after antipsychotic cessation  
 Duration of antipsychotic treatment in first episode psychosis 
 <6m 6m to  
<1yr 
















5.05 2.54 1.39 0.74 0.08 












* Adjusted subdistribution hazard ratio and 95% confidence interval. Adjusted for age, sex, calendar year, 
diagnosis (schizophrenia vs. other non-affective psychosis), percentage of days spent as inpatient during first 
antipsychotic exposure, history of substance misuse diagnosis, and antipsychotic type (using neuroscience 
based nomenclature groupings). The subdistribution hazard ratio should be interpreted as the difference in rate 
between exposure groups in patients who are event free (e.g., not been hospitalized) or have experienced a 
competing event (restarting antipsychotic medication or death).  
 
